Advances in Engineered Bacteria for Cancer Therapy
Precision medicine and engineering.,
Год журнала:
2025,
Номер
unknown, С. 100017 - 100017
Опубликована: Фев. 1, 2025
Язык: Английский
Antitumor Efficacy of Interleukin 12-Transfected Mesenchymal Stem Cells in B16-F10 Mouse Melanoma Tumor Model
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 278 - 278
Опубликована: Фев. 20, 2025
Background/Objectives:
Mesenchymal
stromal
cells
(MSCs)
hold
the
potential
for
tumor-targeted
gene
delivery
due
to
their
ex
vivo
manipulability,
low
immunogenicity,
scalability,
and
inherent
tumor-homing
properties.
Despite
widespread
use
of
viral
vectors
MSC
genetic
modification,
safety
concerns
have
prompted
interest
in
non-viral
alternatives,
such
as
electrotransfer
(GET).
This
study
aimed
optimize
GET
parameters
MSCs
transfection,
assess
biodistribution
after
administration,
evaluate
therapeutic
interleukin-12
(IL-12)-modified
a
mouse
melanoma
model.
Methods:
Human
were
isolated
from
umbilical
cords
under
ethically
approved
protocols.
protocols
optimized
using
fluorescent
reporter
transfection
efficiency
cell
viability.
was
examined
following
intravenous
intratumoral
injections
murine
tumor
models
luminescent
gene.
The
efficacy
IL-12-modified
assessed
syngeneic
Results:
Optimized
achieved
80%
viability
90%.
Biodistribution
studies
demonstrated
effective
retention
injections,
whereas
administration
resulted
predominant
localization
lungs.
injected
intratumorally
significantly
inhibited
growth,
delaying
progression
by
five
days
compared
controls.
Conclusions:
conditions
enabled
high-efficiency,
high-viability
facilitating
vehicles
localized
cytokine
delivery.
While
innate
tropism
not
conclusively
demonstrated,
highlights
reliable
platform
underscores
promise
therapy.
Язык: Английский
Clinical Trials of Cancer Immunogene Therapies in Companion Animals: An Update (2017–2024)
Veterinary Sciences,
Год журнала:
2025,
Номер
12(4), С. 329 - 329
Опубликована: Апрель 3, 2025
This
review
summarizes
the
findings
of
veterinary
clinical
trials
on
immunogene
therapy
published
between
2017
and
2024.
Various
tumor
types,
including
melanoma
(canine
feline),
mastocytoma
(canine),
mammary
adenocarcinoma
osteosarcoma
sarcoid
(equine),
were
treated
using
diverse
strategies.
Non-viral
vectors
predominantly
used
to
deliver
genes
encoding
tumor-associated
antigens,
cytokines,
or
suicide
enzymes.
Among
these
non-viral
methods,
electrotransfer
was
most
commonly
employed
technique
for
introducing
therapeutic
into
cells.
Generally,
procedures
resulted
in
minimal
no
adverse
side
effects,
animals
often
showed
significant
improvements,
such
as
enhanced
quality
life,
delayed
suppressed
recurrence
metastasis,
increased
survival
times.
Some
innovative
approaches
hold
great
potential
adjunct
therapies
standard
treatments.
The
promising
outcomes
from
studies
companion
strongly
support
their
application
oncology
provide
valuable
preclinical
data
(including
safety
assessments
proof-of-concept
studies)
analogous
human
trials.
Язык: Английский
The Cancer Chimera: Impact of Vimentin and Cytokeratin Co-Expression in Hybrid Epithelial/Mesenchymal Cancer Cells on Tumor Plasticity and Metastasis
Cancers,
Год журнала:
2024,
Номер
16(24), С. 4158 - 4158
Опубликована: Дек. 13, 2024
The
epithelial–mesenchymal
transition
(EMT)
program
is
critical
to
metastatic
cancer
progression.
EMT
results
in
the
expression
of
mesenchymal
proteins
and
enhances
migratory
invasive
capabilities.
In
a
small
percentage
cells,
stemness-associated
genes
that
provide
advantage.
Although
had
been
viewed
as
binary
event,
it
has
recently
become
clear
leads
spectrum
phenotypes,
including
hybrid
epithelial/mesenchymal
(E/M)
cells
have
significantly
greater
capability
than
on
epithelial
or
ends
spectrum.
As
E/M
are
rarely
observed
physiological,
non-diseased
states
adult
human
body,
these
potential
biomarkers
drug
targets.
Hybrid
distinguished
by
co-expression
proteins,
such
intermediate
filament
cytokeratin
(CK;
epithelial)
vimentin
(VIM;
mesenchymal).
filaments
extensively
used
for
pathological
characterization
detection
aggressive
carcinomas,
little
known
regarding
interactions
between
CK
VIM
when
co-expressed
cells.
This
review
describes
characteristics
with
focus
unique
CK.
We
will
discuss
structures
functions
two
how
they
may
interact
Additionally,
we
what
about
cell-surface
their
predictive
therapeutic
Язык: Английский